Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression

Clinical Cancer Research

Volumn 5, Issue 8, 1999, Pages 2094-2102

  Robert, Catherine ^a,b   Bolon, Isabelle ^c   Gazzeri, Sylvie ^a   Veyrenc, Sylvie ^a   Brambilla, Christian ^a   Brambilla, Elisabeth ^a,b  

^a Inst Natl S Rech Med CJF 97 01   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE;

ARTICLE; CANCER INVASION; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG FIBROBLAST; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR GROWTH; TUMOR VOLUME;

CARCINOMA, NEUROENDOCRINE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; SERINE PROTEINASE INHIBITORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032784649     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Brambilla, E., Moro, D., Veale, D., Brichon, P. Y., Stoebner, P., Paramelle, B., and Brambilla, C. Basaloid carcinomas of lung a new phenotypic entity with prognosis significance. Hum. Pathol., 23: 993-1003, 1992.
2. Travis, W. D., Linnoila, R. I., Tsokos, M. G., Hitchcock, C. L., Cutler, G. B., Nieman, L., Chrousos, G., Pass, H., and Doppman, J. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. Am. J. Surg. Pathol., 15: 529-553, 1991.
3. Pastorino, U., Andreola, S., Tagliabue, E., Pezzella, F., Incarbone, M., Sozzi, G., Buyse, M., Menard, S., Pierotti, M., and Rilke, F. Immunohistochemical markers in stage I lung cancer: relevance to prognosis. J. Clin. Oncol., 8: 2858-2865, 1997.
4. r 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol., 100: 86-92, 1985.
5. Ellis, V., Scully, M. F., and Kakar, V. V. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J. Biol. Chem., 264: 2184-2188, 1989.
6. He, C., Wilhelm, S. C., Pentland, A. P., Marmer, B. L., Grant, G. A., Eisen, A. Z., and Goldberg, G. I. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc. Natl. Acad. Sci. USA, 86: 2632-2636, 1998.
7. De Vries, T. J., Van Muijen, G. N. P., and Ruiter, D. J. The plasminogen activation system in tumor invasion and metastasis. Pathol. Res. Pract., 192: 718-733, 1996.
8. Andreasen, P. A., Kjoller, L., Christensen, L., and Duffy, M. J. The urokinase plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 72: 1-22, 1997.
9. Liu, G., Shuman, M. A., and Cohen, R. L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer, 60: 501-506, 1995.
10. Mueller, B. M., Yu, Y. B., and Laug, W. E. Overexpression of plasminogen activator 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc. Natl. Acad. Sci. USA. 92: 205-209, 1995.
11. Evans, D. M., and Lin, P. L. Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Am. Surg., 61: 692-697, 1995.
12. Jänicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Hôfler, H., and Graeff, H. Urokinase (u-PA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Treat., 24: 195-208, 1993.
13. Nekarda, H., Siewert, J., Schmitt, M., and Ulm, K. Tumor associated proteolytic factors factors u-PA and PAI-1 and survival in totally resected gastric cancer. Lancet, 343: 117, 1994.
14. Sappino, A. P., Busso, N., Belin, D., and Vassali, J. D. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res., 47: 4043-4046, 1987.
15. Pedersen, H., Grondahl-Hansen, J., Francis, D., Osterlind, K., Hansen, H. H., Dano, K., and Brünner, N. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res., 54: 120-123, 1994.
16. Pedersen, H., Brunner, N., Francis, D., Osterlind, K., Ronne, E., Hansen, H. H., Dano, K., and Grondahl-Hansen, J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 54: 4671-4675, 1994.
17. Nagayama, M., Sato, A., Hayakawa, H., Urano, T., Takada, Y., and Takada, A. Plasminogen activators and their inhibitors in non-small cell lung cancer. Cancer (Phila.), 73: 1398-1405, 1994.
18. Papot, H., Pfeiffer, P., Grondahl-Hansen, J., Guldhammer, Skov, B. Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer. Int. J. Oncol., 10: 177-182, 1997.
19. Bolon, I., Gouyer, V., Devouassoux, M., Vandenbunder, B., Wermert, N., Moro, D., Brambilla, C., and Brambilla, E. Expression of c-ets1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am. J. Pathol., 147: 1298-1310, 1995.
20. Bolon, I., Devouassoux, M., Robert, C., Moro, D., Brambilla, C., and Brambilla, E. Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. Am. J. Pathol., 150: 1619-1629, 1997.
21. Travis, W., Colby, T. V., Corrin, B., Shimosato, Y., and Brambilla, E. Histologic Classification of Lung and Pleural Tumours, in press. Geneva: WHO, 1999.
22. Arrigoni, M., Woolner, L., and Bernatz, P. Atypical carcinoid tumors of the lung. J. Thorac. Surg., 64: 413-421, 1972.
23. Travis, W., Rush, W., Fliedler, D., Falk, R., Fleming, M., Gal, A., and Koss, M. Survival analysis of 200 pulmonary neuroendocrine tumors with classification of criteria for typical carcinoid and its separation from typical carcinoid. Am. J. Surg. Pathol., 22: 934-944, 1998.
24. Sordat, I., Chaubert, P., Protiva, P., Guillou, L., Mazzuccheli, L., Saraga, E., Benhattar, J., Trân-Thang, C., Blum, A. L., Dorta, G., and Sordat, B. In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas. Am. J. Pathol., 150: 283-295, 1997.
25. Yoshino, H., Endo, Y., Watanabe, Y., and Sasaki, T. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. Br. J. Cancer, 78: 833-839, 1998.
26. Damjanovich, L., Turzo, C., and Adany, R. Factors involved in the plasminogen activation system in human breast tumors. Thromb. Haemostasis, 71: 684-691, 1994.
27. Christensen, L., Wiborg-Simonsen, A. C., Heegaard, C. W., Moestrup, S. K., Andersen, J. A., and Andreasen, P. A. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen activator inhibitor, urokinase receptor and α2-macroglubuline. Int. J. Cancer, 66: 441-452, 1996.
28. Duggan, C., Kennedy, M. D., Barnes, C., Elvin, P., McDermott, E., O'Higgins, N., and Duffy, M. J. Plasminogen inhibitor type 2 in breast cancer. Br. J. Cancer, 76: 622-627, 1997.
29. Bouchet, C., Spyratos, F., Martin, P. M., Hacene, K., Gentile, A., and Oglobine, J. Prognostic value of urokinase plasminogen activator (u-PA) and plasminogen activator inhibitor PAI-1 and PAI-2 in breast carcinomas. Br. J. Cancer, 69: 398-405, 1994.
30. Schmitt, M., Harbeck, N., Thomssen, C., Wilhelm, O., Reuning, U., Ulm, K., Höfler, H., Jänicke, F., and Graeff, H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemostasis, 78: 285-296, 1997.
31. Kuhn, W., Pache, L., Schmalfeldt Bdettmar, P., Schmitt, M., Jänicke, F., and Graeff, H. Urokinase (u-PA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol., 55: 401-409, 1994.
32. Waltz, D. A., Natkin, L. R., Fujita, R. M., Wei, Y., and Chapman, H. A. Plasmin and plasminogen activator inhibitor type-1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest., 100: 58-67, 1997.
33. Stefansson, S., and Lawrence, D. A. The serpin PAI-1 inhibits cell migration by blocking integrin avb3 binding to vitronectine. Nature (Lond.), 383: 441-443, 1996.
34. Planus, E., Barlovatz-Meimon, G., Rogers, R. A., Bonavaud, S., Ingber, D. E., and Wang, N. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. J. Cell Sci., 110: 1091-1098, 1997.
35. Bajou, K., Noël, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., and Foidart, J. M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med., 4: 923-928, 1998.
36. Taipale, J., and Kessi-Oja, J. Growth factors in the extracellular matrix. FASEB J., 11: 51-59, 1997.
37. Vignaud, J. M., Martinet, Y., and Martinet, N. Role of growth factors in the stromal reaction in non-small cell lung carcinoma. In: Lung Tumors. Fundamental biology and clinical management, pp. 347-364. New-York: Marcel Dekker, Inc., 1998.
38. Keski-Oja, J., Raghow, R., Sawdey, M., Loskutoff, D. J., Postlethwaite, A. E., Kand, A. H., and Moses, H. L. Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-β. J. Biol. Chem., 263: 3111-3115, 1988.
39. Ganesh, S., Sier, C. F. M., Griffioen, G., Vloedgraven, H., De Boer, A., Welwaart, K., Van de Velde, C., Van Krieken, J., Verheijen, J., Lamers, C., and Verspaget, H. W. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res., 54: 4065-4071, 1994.
40. Baker, M. S., Bleakley, P., Woodrow, G. C., and Doe, F. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res., 50: 4676-4684, 1990.
41. Pöllänen, J., Stephenes, R. W., and Vaheri, A. Directed plasminogen activation at the surface of normal and malignant cells. Adv. Cancer Res., 57: 273-328, 1991.
42. Ragno, P., Monturi, N., and Rossi, G. Urokinase-type plasminogen activator inhibitor complexs are not internalized upon binding to the urokinase-type plasminogen activator-receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type 2 plasminogen activator inhibitor complexs with the cell surface. Eur. J. Biochem., 233: 514-519, 1995.
43. Laug, W. E., Cao, X. R., Yu, Y. B., Shimada, H., and Kruithof, E. K. Inhibition of invasion of HT-1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res., 53: 6051-6057, 1993.
44. Dickinson, J. L., Bates, E. J., Ferrante, A., and Antalis, T. M. Plasminogen activator inhibitor type-2 inhibits tumor necrosis factor α-induced apoptosis. J. Biol. Chem., 270: 27894-27904, 1995.